---
title: 'Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in
  case of intolerance to at least rifampicin in Austria, Germany and Switzerland -
  Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the
  German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory
  Society (DGP)'
date: '2023-11-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37931778/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231107170719&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: In December 2022, based on the assessment of new evidence, the World
  Health Organization (WHO) updated its guidelines for the treatment of drug-resistant
  tuberculosis (TB). The evaluation of both, these recommendations, and the latest
  study data, makes it necessary to update the existing guidelines on the treatment
  of at least rifampicin-resistant tuberculosis for the German-speaking region, hereby
  replacing the respective chapters. A shortened MDR-TB treatment of at least 6 month
  using ...
disable_comments: true
---
In December 2022, based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB). The evaluation of both, these recommendations, and the latest study data, makes it necessary to update the existing guidelines on the treatment of at least rifampicin-resistant tuberculosis for the German-speaking region, hereby replacing the respective chapters. A shortened MDR-TB treatment of at least 6 month using ...